Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial

Abstract

We compared the anti-fracture efficacy of teriparatide with risedronate in patients with severe osteoporosis. Among post-menopausal women with severe osteoporosis, the risk of new vertebral and clinical fractures is significantly lower in patients receiving teriparatide than in those receiving risedronate.

Keywords

• severe osteoporosis
• teriparatidem
• risedronate
• fracture risk